Follow-up study of Viaskin Peanut shows significant increase in peanut consumption and treatment benefit in peanut allergic children

DBV Technologies, a clinicalstage specialty biopharmaceutical company, today announced that topline findings from the first 12 months of the OLFUS-VIPES study, or OLFUS, support the long-term…